Search

Your search keyword '"Budaj, Andrzej"' showing total 77 results

Search Constraints

Start Over You searched for: Author "Budaj, Andrzej" Remove constraint Author: "Budaj, Andrzej" Database Supplemental Index Remove constraint Database: Supplemental Index
77 results on '"Budaj, Andrzej"'

Search Results

3. Well-palpable pulse over an occluded radial artery: A case series reporting ultrasound outcomes

4. A novel technique for iatrogenic pseudoaneurysm obliteration with ultrasound-guided thrombin foam injection

5. Sex-specific presentation, care, and clinical events in individuals admitted with NSTEMI: the ACVC-EAPCI EORP NSTEMI registry of the European Society of Cardiology

6. A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial Infarction

8. Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

9. Association of Cardiac Biomarkers With Major Adverse Cardiovascular Events in High-risk Patients With Diabetes: A Secondary Analysis of the DECLARE-TIMI 58 Trial

12. Effects of early myocardial reperfusion and perfusion on myocardial necrosis/dysfunction and inflammation in patients with ST-segment and non-ST-segment elevation acute coronary syndrome: results from the PLATelet inhibition and patients Outcomes (PLATO) trial

13. Interleukin 6 and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Chronic Coronary Syndrome

14. Risk markers of incident atrial fibrillation in patients with coronary heart disease.

16. A multinational registry to study the characteristics and outcomes of heart failure patients: The global congestive heart failure (G-CHF) registry.

17. In patients with stable coronary heart disease, low-density lipoprotein-cholesterol levels < 70 mg/dL and glycosylated hemoglobin A1c < 7% are associated with lower major cardiovascular events.

18. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

19. Antiplatelet therapy in patients with myocardial infarction without obstructive coronary artery disease

20. Assessment of quality of care of patients with ST-segment elevation myocardial infarction

22. Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus

24. Hospitalization Among Patients With Atrial Fibrillation and a Recent Acute Coronary Syndrome or Percutaneous Coronary Intervention Treated With Apixaban or Aspirin

26. Characterization of cardiovascular clinical events and impact of event adjudication on the treatment effect of darapladib versus placebo in patients with stable coronary heart disease: Insights from the STABILITY trial.

27. Balancing the risk of spontaneous ischemic and major bleeding events in acute coronary syndromes.

28. Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial

29. Association of Fibroblast Growth Factor 23 With Recurrent Cardiovascular Events in Patients After an Acute Coronary Syndrome: A Secondary Analysis of a Randomized Clinical Trial

30. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial

31. Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial

32. Long-term Tolerability of Ticagrelor for the Secondary Prevention of Major Adverse Cardiovascular Events: A Secondary Analysis of the PEGASUS-TIMI 54 Trial

33. Tooth loss is independently associated with poor outcomes in stable coronary heart disease

34. Abstract 10470: Projected Lifetime Benefits of Alirocumab in Patients After Acute Coronary Syndrome

35. Periodontal disease in patients with chronic coronary heart disease: Prevalence and association with cardiovascular risk factors

37. Comparative prognostic value of T-wave inversion and ST-segment depression on the admission electrocardiogram in non–ST-segment elevation acute coronary syndromes.

38. Effect of Radial Versus Femoral Access on Radiation Dose and the Importance of Procedural Volume: A Substudy of the Multicenter Randomized RIVAL Trial.

39. Bleeding during treatment with aspirin versus apixaban in patients with atrial fibrillation unsuitable for warfarin: the apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for...

41. Outcome and causes of renal deterioration evaluated by serial cystatin C measurements in acute coronary syndrome patients—Results from the PLATelet inhibition and patient Outcomes (PLATO) study.

43. Prognostic significance of electrocardiographic-determined left ventricular hypertrophy and associated ST-segment depression in patients with non–ST-elevation acute coronary syndromes.

44. In-Hospital Outcomes Associated With Fibrinolytic and Thienopyridine Use in Patients With ST-Segment Elevation Acute Myocardial Infarction. The Global Registry of Acute Coronary Events.

45. Glucose levels compared with diabetes history in the risk assessment of patients with acute myocardial infarction.

46. Fondaparinux compared to enoxaparin in patients with acute coronary syndromes without ST-segment elevation: Outcomes and treatment effect across different levels of risk.

47. Reperfusion in Patients With Renal Dysfunction After Presentation With ST-Segment Elevation or Left Bundle Branch Block: GRACE (Global Registry of Acute Coronary Events).

48. Effect of enoxaparin versus unfractionated heparin in diabetic patients with ST-elevation myocardial infarction in the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment–Thrombolysis In Myocardial Infarction study ...

49. Relationship of ST elevation in lead aVR with angiographic findings and outcome in non-ST elevation acute coronary syndromes.

50. Use of proven therapies in non–ST-elevation acute coronary syndromes according to evidence-based risk stratification.

Catalog

Books, media, physical & digital resources